|22nd February 2021||Emma Reeve||6,260||Exercise of derivative||$8.04||$50,330.40|
|22nd February 2021||Emma Reeve||6,260||Open or private sale||$37.60||$235,373.50|
|19th February 2021||Emma Reeve||4,010||Open or private sale||$37.71||$151,217.90|
|19th February 2021||Emma Reeve||4,010||Exercise of derivative||$8.04||$32,240.40|
|18th February 2021||Emma Reeve||1,100||Exercise of derivative||$8.04||$8,844.00|
|18th February 2021||Emma Reeve||1,100||Open or private sale||$37.58||$41,343.06|
|17th February 2021||Emma Reeve||410||Exercise of derivative||$8.04||$3,296.40|
|17th February 2021||Group L P Column||10,000||Open or private sale||$36.95||$369,503.00|
|17th February 2021||Emma Reeve||410||Open or private sale||$37.56||$15,397.84|
|2nd February 2021||Mark A Goldsmith||5,000||Exercise of derivative||$1.12||$5,600.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel therapeutics in the field of epigenetics. Its product candidates include CPI-0610, CPI-1205, and CPI-0209.